Plain-English translation of NCT07155525 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a tissue adhesive glue called Glubran® 2 can help prevent a serious complication called pancreatic fistula after pancreaticoduodenectomy—a major surgery to remove pancreatic tumors. The medication is a special surgical adhesive that hardens quickly when it touches body tissue, potentially sealing small leaks at the surgical site. Half of participants will receive the standard surgery alone, and half will have this treatment applied during their surgery.
Pancreatic fistula is the most common serious problem after this type of pancreas surgery, happening in more than half of patients with soft pancreatic tissue. Researchers believe this treatment could provide extra reinforcement and sealing to reduce these dangerous leaks.
You likely qualify if…
You likely don't qualify if…
You will undergo pancreaticoduodenectomy surgery, and the randomization happens during the operation itself. Half of participants receive standard surgical reconstruction, while the other half also have 1–2 mL of the surgical glue applied to the surgical site. After surgery, you'll have daily measurements of amylase (an enzyme) from your surgical drains on days 1, 3, and 5, plus imaging scans to check for complications. You'll receive standard post-operative care including antibiotics and drain management according to established clinical guidelines.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Egypt